Fate Therapeutics Inc FATE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $4.10
- Day Range
- $4.05–4.50
- 52-Week Range
- $1.63–8.83
- Bid/Ask
- $4.07 / $4.18
- Market Cap
- $461.96 Mil
- Volume/Avg
- 2.0 Mil / 2.6 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.29
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 181
- Website
- https://www.fatetherapeutics.com
Comparables
Valuation
Metric
|
FATE
|
CLDX
|
TYRA
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.09 | 5.54 | 3.76 |
Price/Sales | 6.29 | 299.58 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
FATE
CLDX
TYRA
Financial Strength
Metric
|
FATE
|
CLDX
|
TYRA
|
---|---|---|---|
Quick Ratio | 8.11 | 13.69 | 13.27 |
Current Ratio | 8.48 | 13.87 | 13.80 |
Interest Coverage | — | — | — |
Quick Ratio
FATE
CLDX
TYRA
Profitability
Metric
|
FATE
|
CLDX
|
TYRA
|
---|---|---|---|
Return on Assets (Normalized) | −20.19% | −30.49% | −22.50% |
Return on Equity (Normalized) | −27.64% | −33.19% | −23.73% |
Return on Invested Capital (Normalized) | −25.38% | −32.85% | −27.79% |
Return on Assets
FATE
CLDX
TYRA
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Mlpyhmjt | Qjz | $545.9 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fldmzyxs | Wggcmh | $105.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fzpcbkx | Rrcznh | $103.7 Bil | |
MRNA
| Moderna Inc | Mgftdnwg | Zpc | $47.9 Bil | |
ARGX
| argenx SE ADR | Thhwsjqk | Ftxpn | $22.9 Bil | |
BNTX
| BioNTech SE ADR | Jdcwvzxr | Frlc | $22.3 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lwcxchkkr | Mddfxy | $19.3 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Wqdmgsf | Ctbkhv | $15.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qfyfczprf | Ntfmvm | $12.8 Bil | |
INCY
| Incyte Corp | Gsrqvzrj | Hblhbn | $12.1 Bil |